Skip to Main Content

INFORMATION FOR

    Metastatic Surgery

    September 30, 2025

    What is the rationale for cytoreductive radical prostatectomy trial?

    ID
    13463

    Transcript

    • 00:02For these patients who have
    • 00:04metastatic prostate cancer, then the
    • 00:06current standard of care is
    • 00:07systemic therapy, or some so
    • 00:09called the hormonal therapy,
    • 00:11plus or minus chemotherapy.
    • 00:13And again,
    • 00:15that and those
    • 00:16agents,
    • 00:17are given that results of
    • 00:19about a three year survival,
    • 00:20median survival for these patients
    • 00:22right now. So,
    • 00:24what I'm trying to do
    • 00:25right now in our study
    • 00:27is, is that does a,
    • 00:29site reduction or removing
    • 00:32the local disease,
    • 00:34help treat systemic disease? So
    • 00:36what I mean by that
    • 00:37is, is that, if we
    • 00:39take out
    • 00:40the site where the cancer
    • 00:41came from, then will the
    • 00:43hormonal therapy, will the chemotherapy
    • 00:45be more effective
    • 00:47against prostate cancer that has
    • 00:49gone to the bones, to
    • 00:50the lymph nodes, or liver,
    • 00:51or other part of the
    • 00:52body?